Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. by Dankort, David et al.
UCSF
UC San Francisco Previously Published Works
Title
Braf(V600E) cooperates with Pten loss to induce metastatic melanoma.
Permalink
https://escholarship.org/uc/item/4j37r8pp
Journal
Nature genetics, 41(5)
ISSN
1061-4036
Authors
Dankort, David
Curley, David P
Cartlidge, Robert A
et al.
Publication Date
2009-05-01
DOI
10.1038/ng.356
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
BRafV600E cooperates with Pten silencing to elicit metastatic 
melanoma
David Dankort1,*,‡, David P. Curley3,*, Robert A. Cartlidge1, Betsy Nelson3, Anthony N. 
Karnezis2, William E. Damsky Jr.3, Mingjian J. You4,#, Ronald A. DePinho4, Martin 
McMahon1,¶, and Marcus Bosenberg3,¶,§
1
 Cancer Research Institute & Department of Cell and Molecular Pharmacology, Helen Diller 
Family Comprehensive Cancer Center, University of California, San Francisco CA 94143
2
 Cancer Research Institute & Department of Pathology, Helen Diller Family Comprehensive 
Cancer Center, University of California, San Francisco CA 94143
3
 Department of Pathology, University of Vermont College of Medicine, Burlington, VT 05405
4
 Belfer Institute for Applied Cancer Science, Departments of Medical Oncology, Medicine & 
Genetics, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115
Abstract
Mutational activation of BRAF is the earliest and most common genetic alteration in human 
melanoma. Hence, to build a model of human melanoma, we generated mice with conditional 
melanocyte-specific expression of BRafV600E. Upon induction of BRafV600E expression, mice 
developed benign melanocytic hyperplasias that failed to progress to melanoma over 15-20 
months. By contrast, expression of BRafV600E combined with Pten tumor suppressor gene 
silencing elicited development of melanoma with 100% penetrance, short latency and with 
metastases observed in lymph nodes and lungs. Melanoma was prevented by inhibitors of mTorc1 
(Rapamycin) or MEK1/2 (PD325901) but, upon cessation of drug administration, mice developed 
melanoma indicating the presence of long-lived melanoma-initiating cells in this system. 
Importantly, combined treatment with Rapamycin and PD325901 led to shrinkage of established 
melanomas. These mice, engineered with a common genetic profile to human melanoma, provide 
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an excellent system to study melanoma’s cardinal feature of metastasis and for pre-clinical 
evaluation of agents designed to prevent or treat metastatic disease.
Malignant melanoma is noted for its aggressive clinical behavior, a propensity for lethal 
metastasis and striking therapeutic resistance. This dismal clinical picture, coupled with an 
alarming increase in incidence, has motivated efforts to understand the genetic 
underpinnings of melanoma initiation and progression and translate such insights into 
effective preventive and therapeutic strategies for this dreaded disease 1,2.
Several key genetic lesions governing melanoma initiation and progression have been 
identified, the earliest and most common being a point mutation (T1799A) in the BRAF 
proto-oncogene, which is detected in ∼65% of patients 1,3-7. BRAFT1799A encodes 
BRAFV600E, a constitutively active protein serine kinase that elicits sustained activation of 
the BRAF→MEK1/2→ERK1/2 MAP kinase pathway. While contributing to the aberrant 
pathophysiological characteristics of the melanoma cell 8,9, oncogenic activation of BRAF 
in melanocytes is insufficient for full malignant conversion owing to activation of 
senescence 10,11. Hence, progression to malignant melanoma is invariably accompanied by 
silencing of one or more tumor suppressor genes, most commonly PTEN, INK4A and/or 
ARF 5,12-14. Of relevance to this study, the combination of mutated BRAF and silencing of 
PTEN expression is common in human melanoma (∼20%), although genetic evidence for 
BRAF/PTEN cooperation in this disease has not been obtained to date 14-16.
To understand and validate the role of such genetic events and their interactions in 
melanoma initiation, progression and response to therapy, we have generated a conditional 
mouse model of BRafV600E-induced/Pten deficient metastatic melanoma. This genetic model 
recapitulates key pathophysiological aspects of the human disease and offers exquisite 
control over the timing and location of melanoma initiation. Moreover, we demonstrate the 
utility of this model in the evaluation of pharmacologic agents that target key signaling 
pathways linked to these signature events in the melanoma cell, demonstrating the utility of 
this disease model in pre-clinical experimental therapeutics.
RESULTS
BRafV600E promotes benign melanocytic hyperplasia in vivo
BRafCA mice harbor a germ-line conditional BRafV600E allele, the expression of which is 
initiated at physiological levels under the control of the gene’s chromosomal promoter by 
the action of Cre recombinase (Fig. 1a) 17. When the BRafCA allele was combined with a 
constitutively active Cre transgene under the control of the Tyrosinase promoter (Tyr::Cre, 
Tec1) no viable offspring were obtained (Supplementary table 1) 18. Similarly, compound 
BRafCA and Dopachrome tautomerase promoter-directed Cre (Dct::Cre) transgenic mice 
succumbed within 3 months of age 19 (Matzen et al., Submitted). To circumvent lethality 
associated with embryonic expression of BRafV600E we utilized a Tyr::CreER transgene, 
which encodes conditionally active CreERT2 specifically in melanocytes (Fig. 1a) 20. In the 
absence of 4-hydroxytamoxifen (4-HT), Tyr::CreER; BRafCA/+ mice displayed no 
discernable phenotype over 18 months of observation (n≥50, Fig. 1b; i). However, topical 
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administration of 4-HT to either fur bearing or glabrous skin or systemic 4-HT 
administration led to the appearance of highly pigmented lesions that were detected by 
21-28 days after 4-HT administration (Fig. 1c; i). Such lesions were not detected in 4-HT 
treated Tyr::CreER mice indicating that they require the conversion of the BRafCA allele to 
BRafV600E (Supplementary Fig. 1a) 20.
BRafV600E-induced pigmented lesions were frequently located at the dermal/epidermal 
junction with extension into the dermis, as is seen in human compound melanocytic nevi 
(Fig. 1c; iii). Other melanocytic proliferations formed in the dermis with no apparent 
junctional component. BRafV600E-induced pigmented lesions appeared only in regions of the 
skin to which 4-HT was applied and were not induced by topical administration of solvent as 
control (Supplementary Fig. 1). Occasionally, when mice were topically administered with 
high concentrations of 4-HT, we observed periocular lesions on the face and on the glabrous 
skin of the paws, most likely due to grooming behavior (Supplementary Fig. 1b & c). 
However, by reducing the amount of 4-HT administered, we could elicit spatially restricted 
melanocytic lesions with no evidence of inappropriate spreading to untreated sites.
To determine if BRafV600E-induced pigmented lesions would progress spontaneously to 
malignant melanoma, we monitored 35 4-HT treated Tyr::CreER; BRafCA mice over 15-20 
months. Although 2 mice developed small papular pigmented lesions, these lesions were not 
considered malignant in nature based on their lack of significant invasion or metastasis, the 
small/self-limited tumor growth, the banal cytologic features of the cells and the absence of 
aberrant mitotic figures within the lesions (Fig. 1e; i-iii). These data are consistent with the 
hypothesis that BRAFV600E expression in human melanocytes promotes an initial phase of 
proliferation that is subsequently restrained from malignant progression by engagement of a 
cell cycle arrest program with features of senescence, reflecting the clinical observation of 
growth arrest of pigmented nevi in humans 10,21.
In addition, we generated a small number of Tyr::CreER mice that were homozygous for 
BRafCA to assess the impact of two copies of the BRafV600E allele (n=6). Topical 4-HT 
administration to the ear, tail or flank of these mice led to the appearance of benign 
melanocytic hyperplasias that were significantly larger and more highly pigmented than in 
mice heterozygous for BRafCA expressing only one copy of BRafV600E (Fig. 1d; i-iv 
respectively). Indeed, this phenotypic presentation was so reproducible that mice could be 
genotyped (BRafCA/+ vs. BRafCA/CA) based on the size and pigmentation of the melanocytic 
lesions that developed. These data indicate that BRafV600E gene dosage exerts a 
physiologically relevant impact on melanocyte proliferation, an experimental observation 
that may rationalize the observation of increased copy number of oncogenic BRAF in human 
melanoma and other tumors 22,23.
BRafV600E cooperates with Pten silencing to promote invasive, metastatic melanoma
Human melanomas expressing BRAFV600E often display activation of the PI3′-
kinase→PDK→AKT pathway through silenced expression of the PTEN tumor suppressor 
gene 14,15,22. To model this genetic profile, we generated Tyr::CreER; BRafCA mice that 
were also homozygous for either one of two different conditional Pten alleles. One allele 
(PtenloxP-neo) conditionally deletes Pten exons 4 and 5 24. The second allele (not previously 
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described) permits Cre-mediated deletion of Pten exon 5. (For purposes of clarity we refer to 
these alleles as Ptenlox4-5 and Ptenlox5 respectively). Importantly, the action of Cre 
recombinase on both alleles leads to deletion of exons that encode amino acids essential for 
the Pten’s PI3′-lipid phosphatase activity 24.
In striking contrast to BRafV600E-induced melanocytic neoplasia (Fig 1), 4-HT treatment of 
Tyr::CreER; Ptenlox4-5/lox4-5 or Tyr::CreER; Ptenlox5/lox5 mice failed to elicit any 
melanocytic phenotype over ∼18 months (n=20). These data are consistent with 
observations that Dct::Cre; Ptenlox/lox mice do not develop melanoma unless treated with 
carcinogen 25. However, 7-10 days following 4-HT administration, all Tyr::CreER; 
BRafCA; Ptenlox/lox mice displayed a dramatic expansion of highly pigmented cells 
regardless of where the 4-HT was administered to the skin and regardless of what Pten allele 
was used (Figs. 2a-c). Indeed, so dramatic was the cooperation between BRafV600E and Pten 
silencing that confluent melanocytic proliferation/hyperplasia was observed in 4-HT treated 
regions of the skin of Tyr::CreER; BRafCA; Ptenlox/lox mice. By contrast, treatment with 
DMSO solvent control was without effect (Figs. 2g-i and Supplementary Fig. 3b). 
Abrogation of Pten expression was confirmed by Western blotting analysis of extracts of 
primary lesions derived from 4-HT treated Tyr::CreER; BRafCA; Ptenlox5/lox5 mice 
(Supplementary Fig. 4). Pigmented melanoma cells were found throughout the dermis, 
subcutis and displayed pagetoid spread into the epidermis (Figs. 2h, i & k). Moreover, there 
was rapid emergence of highly pigmented malignant lesions elicited by 4-HT in the face, 
flank or tail skin, the location of which could be highly restricted by topical administration 
of low dose 4-HT (Figs. 2d-f and Supplementary Figs. 3a & c). These lesions progressed 
rapidly to advanced malignancy such that all Tyr::CreER; BRafCA; Ptenlox/lox mice required 
euthanasia 25-50 days following 4-HT administration (Fig. 2m).
Histological analysis of primary skin lesions revealed highly pigmented cells with variably 
shaped enlarged nuclei containing clumped chromatin, prominent nucleoli and atypical 
mitoses (Fig. 2l). In addition, the melanocytic origin of cells in the lesions was confirmed by 
the presence of abundant melanin and by immunostaining with α-PEP1 to detect expression 
of Tyrosinase related protein 1 (Figs. 2j & k) 26.
To further document the rate-limiting role of Pten in constraining malignant progression, we 
followed a small number of 4-HT treated Tyr::CreER; BRafCA mice that were heterozygous 
for Ptenlox4/5 allele. These mice initially developed benign melanocytic lesions similar to 
those observed in Tyr::CreER; BRafCA mice. However, they eventually developed focal 
malignant melanomas that we believe are most likely due to stochastic silencing of the wild-
type Pten allele, as has been observed with other tumor suppressor genes (Supplementary 
Fig. 2).
BRafV600E; Pten-/- melanoma cells are invasive and metastatic
At euthanasia Tyr::CreER; BRafCA; Ptenlox/lox mice were subjected to complete 
histopathologic survey for evidence of melanoma invasion and metastasis. As described 
above, all mice analyzed had evidence of melanoma cells throughout the dermis with 
evidence of invasion into the subcutis (Fig. 2). In addition, spread of melanoma was 
observed into the regional draining lymph nodes in 100% of mice with expansile growth 
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noted in most mice (Fig. 3a-c). This was also noted in mice with localized tumors in the 
distal region of the tail that had clear evidence of pigmented cells in the iliac lymph nodes 
(Fig. 3d and Supplementary Fig. 3c) and lungs (data not shown). Examination of the lungs 
revealed visible evidence of at least one and, in many cases, multiple nests of metastatic 
melanoma cells (Figs. 3e-g). These data indicate that activated BRafV600E and Pten 
deficiency cooperate to produce primary cutaneous malignant melanoma with robust 
capacity to invade into the skin and to metastasize to draining lymph nodes and distal organs 
that are commonly targeted in the human disease.
Prevention and therapy of BRafV600E-induced melanomas by pharmacological inhibition of 
MEK1/2 and mTorc1
Melanoma is noted for its striking resistance to chemotherapy, although there are anecdotal 
reports of dramatic responses to therapy targeted against mutated c-KIT in humans 13,27. 
Consequently, we wished to determine if targeted inhibition of downstream effectors of 
BRafV600E or PI3′-kinase signaling could prevent the development of melanoma in this 
model system. To do so, we utilized specific and selective inhibitors of MEK1/2 
(PD325901) or mTorc1 (Rapamycin), which are downstream of BRafV600E or PI3′-kinase 
respectively 28,29. Melanoma was initiated in adult Tyr::CreER; BRafCA; Ptenlox/lox mice 
by topical administration with 4-HT. Either 1 day (Rapamycin, Fig. 4a) or 1 week 
(PD325901, Fig. 5a) later the mice were treated systemically either with the relevant solvent 
control or with Rapamycin (7.5mg/kg) or PD325901 (15mg/kg) for 3 or 6 weeks 
respectively. Solvent treated mice rapidly developed melanoma that required euthanasia 
within 3-6 weeks (Figs. 4b & 5b, panel i). By contrast, treatment with either Rapamycin or 
PD325901 dramatically inhibited melanoma formation, such that by the time all of the 
solvent treated mice were euthanized, drug treated mice were alive and showed no signs of 
melanoma formation (Figs. 4b & 5b, panel ii).
To determine if treatment with either Rapamycin or PD325901 had completely eliminated 
melanoma cells initiated by 4-HT administration, drug treatment was ceased in both groups 
of animals with the animals monitored for an additional 3-11 weeks (Figs. 4c & 5c). 
Regardless of the drug employed, all of the animals subsequently developed malignant 
melanoma requiring their euthanasia within 5-11 weeks following cessation of drug 
administration (Figs. 4c, 5b, panel iii & 5c). These data indicate that the prevention of 
melanoma in the drug treated mice was not due to a technical flaw in the activation and 
function of CreER following 4-HT administration. Moreover, these data are consistent with 
the presence of latent melanoma-initiating cells that arise shortly after the CreER activation 
and that can survive extended exposure to agents that target signaling pathways essential for 
the melanoma cell division cycle and survival.
To determine if melanomas that recur following cessation of MEK1/2 inhibitor treatment are 
resistant to re-treatment of mice with this agent, melanoma was initiated in a cohort of 10 
three week old Tyr::Cre; BRafCA; Ptenlox4-5/lox4-5 mice. 10 days later all mice were treated 
systemically with PD325901 for a period of 6 weeks. At this time, consistent with results 
described above, none of the mice displayed any signs of melanoma. Upon cessation of 
PD325901 administration the mice were left untreated for a period of 8 weeks. At this time 
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mice were randomized into two groups of 5, one of which was administered solvent control 
(Group A) and the other PD325901 (Group B) for a further 6 weeks. As described above, 
Group A mice treated only once with PD325901 succumbed to disease 8-12 weeks 
following cessation of drug administration (Fig. 5d). By contrast, Group B mice that 
received 2 cycles of PD325901 remained alive at a time when all of the Group A mice had 
been euthanized. However, all Group B mice displayed signs of melanoma re-growth which, 
while not requiring euthanasia, strongly suggested that these mice would eventually 
succumb to disease. Regardless, these data indicate that mice treated once with PD325901 to 
prevent melanomagenesis remain sensitive to the anti-melanoma action of a second round of 
PD325901 administration.
Results described above document the potent melanoma prevention activity of PD325901 
and Rapamycin. However, to determine if these agents can elicit regression of pre-existing 
tumors in mice, melanoma was initiated in a group of 20 Tyr::Cre; BRafCA; Ptenlox5/lox5 
mice by local administration of 4-HT to back skin (Supplementary Fig. 3a). 3 weeks later, 
when the animals had readily measurable melanoma lesions, mice were randomly divided 
into 4 groups that were administered either solvent control (Vehicle), PD325901 (PD, 
12.5mg/kg), Rapamycin (Rapa, 7.5mg/kg) or the combination of both Rapamycin and 
PD325901 (PD+Rapa) at the same dose used in the single agent arms (Fig. 6a). Mice were 
treated with these agents for 3 weeks with tumor size measured every day. Melanoma 
lesions in the vehicle treated animals progressed steadily over the time course analyzed and 
had expanded in size in all animals by ∼40% by the end of the experiment (Fig. 6b). By 
contrast, mice treated with either PD325901 or Rapamycin as single agents led to striking 
inhibition of tumor growth but with little or no evidence of tumor regression. By contrast, 
mice treated with a combination of Rapamycin and PD325901 displayed a ∼20% reduction 
in tumor size that was statistically significant. These data suggest that the combination of 
MEK1/2 and mTorc1 inhibition can lead to significant tumor shrinkage in the BRafV600E; 
Ptennull melanoma model.
Two hours after the final administration of the various agents in the experiment described 
above, tumor specimens were prepared and stained with: 1. Hematoxylin and Eosin; 2. 
Antisera against Ki67 to assess cell proliferation; 3. Antisera against phospho-ERK1/2 
(pERK1/2) and; 4. Antisera against phospho-4EBP1 (p4EBP1) as indicated (Fig. 6c). The 
last two were to assess the effects of PD325901 or Rapamycin on the relevant signaling 
pathways. Histological analysis of H&E stained sections revealed the presence of viable 
tumor cells in all treatment groups but with an increase in the number of cells with pyknotic 
features of apoptosis in mice treated with PD325901 or PD325901 in combination with 
Rapamycin. Administration of PD325901 or Rapamycin, either alone or in combination led 
to a reduction in cell proliferation as measured by Ki67 staining. As expected, treatment 
with PD325901 led to decreased pERK1/2 staining but had little or no effect on p4EBP1. 
Conversely, treatment with Rapamycin led to decreased p4EBP1 staining but had little or no 
effect on pERK1/2. As expected, the combination of PD325901 and Rapamycin led to 
decreased staining of both pERK1/2 and p4EBP1. These data suggest that, as single agents, 
PD325901 and Rapamycin have predominantly a cytostatic effect on melanoma initiated by 
expression of BRafV600E and extinction of Pten. By contrast, evidence of melanoma 
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regression in mice treated with the combination of PD325901 and Rapamycin suggests that 
these agents may combine to elicit a cytotoxic effect on pre-existing lesions, supported by 
the decrease in tumor size accompanied by an increase in pyknotic tumor cells. However, it 
remains possible that both tumor cell autonomous and non-autonomous effects of these 
agents may contribute to melanoma regression in this experimental system.
Response of BRafV600E-induced melanoma cell lines to pharmacological inhibition of 
MEK1/2 and mTorc1
To characterize potential melanoma cell autonomous effects of Rapamycin and/or 
PD325901, a small number of melanoma derived cell lines were established. One such line 
that grew well in culture (2697T) was derived from a primary cutaneous lesion arising in a 
4-HT treated Tyr::CreER; BRafCA; Ptenlox5/lox5 white mouse and was confirmed to have 
recombined the BRafCA and the Ptenlox alleles by PCR (Supplementary Fig. 5). These cells 
displayed evidence of phosphorylated MEK1/2, ERK1/2, p70S6K and 4EBP1 consistent with 
the genetic alterations in BRaf and Pten that promote melanoma initiation and progression in 
this model (Figs. 7c & d). Treatment of melanoma cells with either Rapamycin (25nM) for 
24 or 48 hours led to 50% inhibition of cell proliferation after 72 hours compared to the 
control (Fig. 7a). The anti-proliferative effects of Rapamycin were accompanied by robust 
inhibition of phospho-p70S6K and 4EBP1, even at the lowest dose tested (2.5nM, Fig. 7d). 
Rapamycin had no effect on the phosphorylation of upstream Akt (T308 or S473) nor on the 
phosphorylation of MEK1/2. Treatment of 2697T cells with PD325901 (2μM) led to 
complete abrogation of cell proliferation (Fig. 7a), a dramatic reduction in S phase cells 
(Fig. 7b) and a modest reduction in cell number at the latest time point. Consistent with this, 
MEK1/2 inhibition elicited a striking reduction of phospho-ERK1/2 with no effect on 
phospho-Akt (Fig. 7c). Moreover, MEK inhibition was accompanied by induction of the 
pro-apoptotic Bcl-2 family protein Bim-EL, cleavage of Caspase 3 (Fig. 7c) and an increase 
in cells with a sub-G1 DNA content (Fig. 7b). These data are similar to those obtained in 
bona fide human melanoma cell lines where regulation of BIM-EL expression downstream 
of oncogenic NRAS or BRAF contributes to suppression of melanoma cell apoptosis 30,31.
DISCUSSION
Mouse models have provided key insights into cancer initiation, progression and therapy, 
and the model described here offers additional distinct and important advantages in the study 
of melanoma and its treatment 32-34. Here, we provide evidence of cooperative interactions 
of two signature mutations found in human melanoma, enabling the generation of a mouse 
that recapitulates hallmark features of the disease, including metastases to relevant organ 
sites. Moreover, the use of BRafCA mice allows accurate modeling of the earliest effects of 
physiological levels of expression of BRafV600E, the purported initiating mutation that 
promotes the conversion of normal human melanocytes to benign nevus cells 4,7. Since 
expression of BRafV600E promotes the development of benign melanocytic hyperplasias that 
fail to progress to malignant melanoma, this system may be used to explore mechanisms 
constraining progression in vivo, to discover and validate tumor suppressor genes governing 
such progression checkpoints and to define the mechanisms driving invasion and metastasis 
10,35,36. Next, use of the Tyr::CreERT2 transgene affords the experimental advantage of 
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exquisite spatial and temporal control over the genetic alterations that initiate melanoma 
formation in mice. Finally, and most notably, we provide evidence that this model is useful 
to study the signaling axis of these key genetic lesions and to assess the impact of agents 
targeting these pathways that may facilitate the development of new strategies to target 
malignant melanoma using conventional and/or targeted therapies 37.
Data presented here are consistent with effects of transgenic over-expression of BRAFV600E 
in zebrafish, which leads to the development of “fish nevi” 38. Moreover, when combined 
with loss of Trp53 expression, BRAFV600E elicited malignant fish melanoma. However, the 
relevance of this combination of genetic events to human melanoma is unclear given the 
relatively low frequency of TP53 mutations in the human disease 1,13. However, these data 
stand in contrast to the reported effects of BRAFV600E over-expression in human 
melanocytes engineered to express the catalytic subunit of telomerase (hTERT), dominant-
negative TP53R248W and CDK4R24C, the last being resistant to the inhibitory effects of the 
melanoma suppressor, p16INK4A 39. In this context, the effects of ectopic BRAFV600E 
expression were benign inducing only mild junctional melanocyte nesting. By contrast, 
ectopic expression of oncogenic variants of RAS (NRASG12V or HRASG12V) or the catalytic 
subunit of PI3′-kinase-α (p110-CAAX) led to striking malignant transformation of such 
“initiated” human melanocytes. It is unclear why the effect of BRAFV600E expression is so 
benign in this context, especially given the dramatic effects of BRAFV600E in zebrafish and 
mice.
Although genetic analysis of human melanomas suggest that mutated BRAF cooperates with 
loss of PTEN expression in melanomagenesis, it has yet to be unequivocally demonstrated 
that such is the case 14,15. However, data presented here demonstrates the ability of 
BRafV600E expression to cooperate with Pten silencing in the genesis of metastatic 
melanoma. It remains to be seen whether PI3′-lipid phosphatase activity is key to Pten’s 
tumor suppressor activity, especially in view of recent demonstrations of effects of Pten on 
other signaling pathways that are independent of its lipid phosphatase activity 40.
A key feature of this model is the ability to control melanoma initiation and progression in 
response to expression of oncogenic BRafV600E in combination with alterations in other 
genes implicated in melanoma initiation, progression or response to therapy such as Ink4a/
Arf, β-catenin, Mitf or various alleles of Mc1r 5,41,42. Given the high frequency of invasion 
and metastasis observed in this model, it may be possible to initiate a primary malignant 
melanoma in a readily accessible site, resect the primary lesion and then monitor the mice 
prospectively for local or distant recurrence. This aspect of the model may afford a detailed 
analysis of mechanisms that promote melanoma cell migration, local invasion and 
metastasis in a manner that more closely recapitulates the clinical course of melanoma 
recurrence in humans.
Metastatic melanoma presents one of the most difficult diseases to treat in medical 
oncology. Indeed, there has not been a major breakthrough in the treatment of this disease in 
over 25 years. Despite the current grim outlook for metastatic melanoma patients, 
considerable excitement has been generated by the identification of genetic and epigenetic 
alterations that contribute to melanomagenesis. All the more so given the accelerated pace of 
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development of pharmacological agents that target key signaling pathways in the melanoma 
cell. However, it remains unclear how best to use such agents in the clinic. Although studies 
with the broad spectrum Raf inhibitor Sorafenib, either as a single agent or in combination 
chemotherapy, have proven disappointing in treating metastatic melanoma this may be due 
to incomplete inhibition of BRAFV600E activity 43,44. Moreover, individual case reports 
indicate that even highly aggressive melanomas expressing mutationally activated c-KIT can 
show a dramatic response to the potent c-KIT inhibitor, Gleevec 27,45. Such observations 
raise hope that pharmacological targeting of relevant molecular target(s) may lead to 
dramatic clinical responses even in late stage melanoma patients. Hence, given the 
prevalence of BRAF and PTEN alterations in melanoma, it may inform the clinical 
development of various new and more selective BRAF, MEK, PI3′-kinase, AKT and mTor 
inhibitors by testing such agents in a validated pre-clinical mouse model 46-48. Experiments 
presented here suggest such agents may have value in melanoma prevention and therapy, but 
the relapse of mice following cessation of drug administration indicates that single agent 
therapy with MEK1/2 or mTor inhibitors is unlikely to cure patients with this disease. 
However, this model system is readily tractable to test combinations of targeted agents or 
targeted therapy combined with conventional cytotoxics or other agents such as 
biochemotherapy or immune based approaches 49. Such studies might provide useful guides 
to the best dose and scheduling of anti-melanoma therapeutics in clinical trials in humans.
METHODS
Mouse breeding, activation of Tyr::CreER transgene and treatment of mice with targeted 
therapeutics
BRafCA, Tyr::CreER and Ptenlox4-5 mice were genotyped as previously described 17,20,24. 
Cre-mediated conversion of BRafCA to BRafVE and the deletion of exons 4 and 5 of Pten 
were assessed by PCR as previously described. Topical administration of 4-
hydroxytamoxifen (4-HT) was performed by preparing a 25-50mg/ml (65-130mM) solution 
of 4-HT (70% Z-isomer, Sigma) in DMSO and applying enough solution to wet the right 
ear, right flank and tail with a small paint brush on post-natal days 2, 3, and 4. For localized 
melanoma induction on the back skin, adult (6-8 weeks of age) mice were treated topically 
with 1-2 μl of 1.9mg/ml (5mM) 4-HT at 6-8 weeks of age using a similar protocol. 
Generalized induction in adult mice was performed by intra-peritoneal injection of 1mg of 
tamoxifen/40g mouse on 3 consecutive days. In this case tamoxifen was prepared as a 
10mg/ml suspension in peanut oil. PD352901 was dissolved in 0.5%(w/v) Hydroxy-propyl-
methylcellulose, 0.2%(v/v) Tween 80 (Sigma) and administered to mice daily by oral 
gavage at a dose of 12.5mg/kg. Rapamycin (LC Laboratories, Woburn, MA) was suspended 
in 0.5%(w/v) methylcellulose and administered to mice daily by oral gavage at a dose of 
7.5mg/kg. Control animals in the melanoma prevention studies were administered with the 
relevant solvent. Tissues were prepared for analysis as previously described 17,20
Generation of mice carrying a Cre-inactivated allele of Pten
A targeting vector was generated in pKO SelectDT-915 using a 12kb fragment of the mouse 
Pten gene by standard techniques. A cassette carrying Pten exon 5 flanked by loxP sites and 
PGK::Neo flanked by FRT sites was then subcloned between the genomic DNA arms. This 
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construct was linearized, transfected into TC1 ES cells and genomic DNA from G418 and 
Diphtheria toxin resistant ES cells were screened by Southern blot and PCR for homologous 
recombination events. Blastocyst injections were carried out with three different targeted 
clones, and transmitting chimaeric mice were bred from CAGG—Flpe transgenic mice to 
generate the Ptenlox5 allele 50. Chimeric mice were mated with FVB/N mice and 
transmission verified by Southern blotting, and PCR with the following primers: 5′-
CTTCGGAGCATGTCTGGCAATGC-3′; 5′-CTGCACGAGACTAGTGAGACGTGC-3′ 
and; 5′-AAGGAAGAGGGTGGGGATAC-3′. All mice were maintained on a mixed 
C57Bl/6 and FVB/N background by random interbreeding.
Melanoma cell line derivation and culture
Melanoma cell lines were derived by physical resection of primary cutaneous lesions 
followed by trituration through a 20-gauge syringe needle and filtration through a 100μm 
nylon cell strainer (BD/Falcon, Bedford, MA before being placed into media. Cell 
suspensions were plated in media (a 1:1 mix of DMEM and Hams F12) supplemented with 
fetal calf serum (5%v/v) and penicillin, streptomycin and glutamine. Serum starved cells 
were treated with different doses of Rapamycin (2.5-250nM as indicated) for 30 minutes 
prior to 10%(v/v) serum stimulation for an additional 20 minutes. Asynchronously growing 
cells in full media were treated with PD325901 (2μM) for different periods of time (24-96 
hours as indicated) with cell proliferation quantified by staining of fixed cells with Crystal 
Violet. Data presented in Figure 6a are results from two separate experiments in which each 
time point was measured in triplicate. Subconfluent cells grown in full melanocyte media 
treated with PD325901 (2uM) or Rapamycin (50nM) were cultured for 46 hours when BrdU 
was added to 20uM for 2 hours. Single cell suspensions fixed in ethanol were stained with 
FITC-labelled BrdU (BD Pharmingen 556028), incubated with propidium iodide (10ug/ml), 
and analyzed with a BD—FACS caliber. Cell extracts were prepared by standard 
techniques, resolved using SDS-polyacryamide gel electrophoresis, Western blots prepared 
by standard techniques, which were probed with commercially available antisera against 
various proteins as indicated 31.
Immunochemistry and immunoblotting
The expression of Tyrosinase (Tyr, Albino), Tyrosinase related protein 1 (Tyrp1, Brown) or 
Tyrosinase related protein 2 (Tyrp2, Slaty) was detected by staining with , 
or  antisera respectively (gift of Dr. Vincent Hearing) 26. Slides were developed 
using and di-amino-benzidine-peroxidase substrate kit (Vector Labs, Burlingame, CA), 
according to the manufacturer’s instructions. The expression and phosphorylation of 
proteins was detected by immunoblotting using appropriate commercially available antisera: 
phospho-4EBP1, phospho-p70S6K, phospho-MEK1/2, total MEK1/2, phospho-ERK1/2; 
total ERK1/2; phospho S473-AKT; phospho-T308-AKT; total AKT; Caspase 3 (all from 
Cell Signaling Technology), Bim-EL (Calbiochem mAb 14A8); and Actin (Sigma).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Benign hyperplasias induced by melanocyte specific expression of BRafV600E
(a) Mice carrying various conditional alleles of BRaf (BRafCA) and/or Pten (Ptenlox4-5 or 
Ptenlox5) were crossed to Tyr::CreER mice with melanocyte specific expression of a 
hormone dependent form of Cre recombinase (CreERT2) 17,20. 4-HT dependent activation 
of CreER leads to melanocyte specific conversion of BRafCA→BRafV600E and the 
conversion of the Ptenlox alleles to null alleles.
BRafCA/+ (b), Tyr::CreER; BRafCA/+ (c) and Tyr::CreER; BRafCA/CA (d) mice were treated 
topically with 4-HT and monitored for 75 weeks for signs of melanocytic proliferation (i). 
Mice were euthanized and skin from the ear (ii, iii) and flank (iv) was stained with 
hematoxylin and eosin and inspected for the presence of pigmented cells. (e) A Tyr::CreER; 
BRafCA/+ mouse developed a papular pigmented lesion ∼60 weeks after topical 
administration of 4-HT (i). This mouse was euthanized and skin sections encompassing the 
lesion were stained with hematoxylin and eosin and inspected for the presence of pigmented 
cells (ii & iii).
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Figure 2. BRafV600E cooperates with Pten loss in the induction of malignant melanoma
(a-c) Tyr::CreER; BRafCA/+; Ptenlox5/lox5 mice were treated topically on the paw with 4-HT 
to elicit BRafV600E and to silence Pten expression. The presence of pigmented lesions was 
assessed 6 (a), 8 (b) and 10 (c) days following 4-HT administration.
(d) Tyr::CreER; BRafCA/+; Ptenlox4-5/lox4-5 (i) were treated topically with 4-HT on the right 
ear. Mice were monitored for 7 weeks.
Tyr::CreER; BRafCA/+; Pten+/+ (e) and Tyr::CreER; BRafCA/+; Ptenlox4-5/lox4-5 (f) were 
treated topically with 4-HT on the right flank. Mice were euthanized at ∼7 weeks with the 
presence of malignant melanoma lesions assessed by visual inspection of the underside of 
the ventral/lateral skin.
Tyr::CreER; BRafCA/+; Ptenlox5/lox5 mice were treated topically on the ear, flank and tail 
with 4-HT. 25 days later mice were euthanized, skin sections were prepared, stained with 
hematoxylin and eosin and examined for the presence of pigmented cells. Almost confluent 
proliferation of densely pigmented cells was observed in the ear and skin (g) that penetrated 
deep into the dermis and the subcutis (h & i) and showed signs of pagetoid spread into the 
epidermis (h & k). Cells in these lesions stained positive with α-PEP1 antisera that detects 
expression of Tyrp1 (j & k). Pigmented cells in the lesions displayed histological 
characteristics of malignant melanoma, including marked cytological atypia, prominent 
nucleoli and aberrant mitotic figures (l)
(j) Kaplan-Meier survival analysis of 4-HT treated Tyr::CreER; BRafCA/+; Pten+/+ (n=22), 
Tyr::CreER; BRaf+/+; Ptenlox4-5/lox4-5 (n=5) and Tyr::CreER; BRafCA/+; Ptenlox4-5/lox4-5 
(n=22) mice. Log rank tests of survival plots of the data indicated a statistically significant 
difference between the following survival curves: Tyr::CreER; BRafCA/+; Pten+/+ versus 
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Tyr::CreER; BRafCA/+; Ptenlox4-5/lox4-5 (p<0.0001) and; Tyr::CreER; BRaf+/+; 
Ptenlox4-5/lox4-5 versus Tyr::CreER; BRafCA/+; Ptenlox4-5/lox4-5 (p<0.0002)
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Figure 3. BRafV600E cooperates with Pten loss in the induction of invasive and metastatic 
melanoma
(a) Tyr::CreER; BRafCA/+; Ptenlox4-5/lox4-5 mice were treated topically on the ear, flank and 
tail with 4-HT. 6 weeks later mice were euthanized and inspected for evidence of pigmented 
cells in the mammary gland lymph node. Tyr::CreER; BRafCA/+; Ptenlox5/lox5 mice were 
treated similarly to those described in (a), euthanized and then inspected by microscopy at 
low (b) and high (c) power for the presence of pigmented cells in the lymph nodes.
(d) A Tyr::CreER; BRafCA/+; Ptenlox5/lox5 mouse was treated topically with 5mM 4-HT in 
100%(v/v) ethanol on the distal tail. The mouse had a visible tumor within 4 weeks but did 
not require euthanasia until 24 weeks later after 4-HT administration. The presence of 
pigmented cells in the Iliac, lumbar, inguinal, axillary and submandibular lymph nodes was 
assessed by stereomicroscopy. Tumor cells were restricted to the iliac nodes (pictured).
(e-f) Tyr::CreER; BRafCA/+; Ptenlox4-5/lox4-5 mice were treated topically on the ear, flank 
and tail with 4-HT. Mice were euthanized 6-7 weeks after 4-HT treatment at which times the 
lungs were excised, cleared of blood and visually inspected for the presence of pigmented 
lesions (e) and (f). Lung sections were prepared, stained with hematoxylin and eosin and 
examined for the presence of pigmented cells in the lung parenchyma (g).
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Figure 4. Prevention of BRafV600E-induced melanomas by Rapamycin
(a) Adult Tyr::CreER; BRafCA/+; Ptenlox5/lox5 mice were treated topically on the ear, flank 
and tail with 4-HT. The next day, mice were randomly assigned to be administered 
Rapamycin (7.5mg/kg, n=5) or solvent control (n=4) for 21 days. Mice were monitored 
daily for the presence of cutaneous malignant melanoma and euthanized according to a 
standard body conditioning score. After 3 weeks of Rapamycin treatment, drug 
administration was ceased and mice were monitored for the presence of cutaneous malignant 
melanoma as described above. Mouse survival was plotted using a Kaplan-Meier survival 
curve (c).
(b) Representative images of a vehicle control (i) or a Rapamycin treated mouse (ii) 
immediately after the end of the 21 day drug administration are presented.
(c) Kaplan-Meier survival curve of vehicle (n=4) or Rapamycin (n=5) treated cohorts of 
mice analyzed in this experiment. All mice were treated for the indicated 21 days as 
indicated in (a).
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Figure 5. Prevention of BRafV600E-induced melanomas by PD325901
(a) Adult Tyr::CreER; BRafCA/+; Ptenlox4-5/lox4-5 mice were treated topically on the ear with 
4-HT. One week later, mice were randomly assigned to be administered PD325901 
(12.5mg/kg, n=12) or the solvent control (n=12) for 6 weeks. Mice were analyzed daily for 
the presence of cutaneous malignant melanoma and euthanized according to a standard body 
conditioning score. After 6 weeks of PD325901 treatment 7 drug treated and 6 control mice 
were euthanized for analysis of skin sections. A further 5 PD325901 treated and 6 control 
mice were monitored over the course of a further 11 weeks without any further drug 
administration. These mice were analyzed for the presence of cutaneous malignant 
melanoma as described above. Mouse survival was plotted using a Kaplan-Meier survival 
curve (c).
(b) Representative anatomical and histological images of skin from 4-HT treated 
Tyr::CreER; BRafCA/+; Ptenlox4-5/lox4-5 mice analyzed after 6 weeks of treatment with 
control solvent (n=6, i) or PD325910 (n=7, ii) or from PD325901 treated mice left without 
further drug administration for an additional 9-11 weeks (iii).
(c) Kaplan-Meier survival curve of vehicle (n=6) or PD325901 (n=5) treated cohorts of mice 
analyzed in this experiment. All mice were treated for the indicated 6 weeks as in (b). Log 
rank tests of survival plots of the data demonstrate a statistically significant difference 
between vehicle and PD325901 treated animals (p=0.0024).
(d) 3 week old Tyr::CreER; BRafCA/+; Ptenlox4-5/lox4-5 mice (n=10) were treated topically 
on the right ear with 4-HT. 10 days later all mice were administered PD325901 (12.5mg/kg) 
for 6 weeks. Drug administration was then ceased for 8 weeks. Mice were then randomized 
into two groups: Group A (blue) was administered vehicle control and Group B (red) was 
administered PD325901 for a further 6 weeks. At the end of this period mice were 
monitored prospectively for disease progression as described above. Mouse survival was 
plotted using a Kaplan-Meier survival curve that demonstrated statistically significant 
difference (p=0.0018) between the groups by log rank tests (e).
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Figure 6. Melanoma regression in response to combination treatment with PD325901 and 
Rapamycin
(a) Melanoma was initiated in a group of 20 Tyr::Cre; BRafCA; Ptenlox/lox mice by local 
administration of 1-2μl of 5mM 4-HT to back skin. 3 weeks later, when the animals had 
readily measurable melanoma lesions, mice were randomly divided into 4 groups that were 
administered either: 1. Solvent control (Vehicle, blue); 2. PD325901 (PD, 12.5mg/kg, red); 
3. Rapamycin (Rapa, 7.5mg/kg, green) or; 4. The combination of both Rapamycin and 
PD325901 (PD+Rapa, orange) for 3 weeks as indicated.
(b) Tumor size in each of the treatment groups described in (a) was measured daily and 
plotted as percentage change in tumor size compared to the starting size. Two-way ANOVA 
analysis demonstrates statistical significance: 1. Vehicle vs Rapa or PD or PD+Rapa 
(p<0.0001); 2. PD vs PD+Rapa (p=0.0024) and; 3. Rapa vs PD+Rapa (p=0.0120).
(c) 2 hours following the final administration of the various agents, mice were euthanized 
and melanoma specimens were prepared for staining with H&E or antisera against Ki67, 
pERK1/2 or p4EBP1 as indicated.
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Figure 7. Inhibition of mouse melanoma cell proliferation by Rapamycin or PD325901 in vitro
A melanoma cell line (2697T) was derived from a 4-HT induced lesion that developed on 
the skin of a white Tyr::CreER; BRafCA/+; Ptenlox5/lox5 mouse. 2697T cells growing 
asynchronously in full media were treated with PD325901 (2μM) or Rapamycin (50nM) as 
indicated. (a) Cell growth was measured using a standard Crystal Violet staining assay. (b) 
DNA synthesis and content was assessed at 48 hours using standard anti-BrdU/Propidium 
Iodide FACS analysis following a 2 hour BrdU pulse. The percentage of cells in each 
portion of the cell cycle is indicated.
(c) 2697T cells, growing asynchronously in full media, were treated with 2μM PD325901 
for 24-72 hours at which time cell extracts were prepared. Expression of Bim-EL, ERK1/2, 
Akt1, Caspase 3 and its active cleavage product (arrowhead) as well as the phosphorylation 
of ERK1/2 and Akt1 was assessed by immunoblotting.
(d) Serum deprived 2697T cells were pre-treated with different concentrations of Rapamycin 
(2.5-250nM) for 30 minutes prior to stimulation with 10%(v/v) fetal calf serum for a further 
20 minutes. Expression of Akt1, MEK1/2 and Actin as well as the phosphorylation of 
4EBP1, p70S6K, and Akt1 (S473 and T308) was assessed by immunoblotting.
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